CO2020016052A2 - Receptores del factor de crecimiento quimérico - Google Patents

Receptores del factor de crecimiento quimérico

Info

Publication number
CO2020016052A2
CO2020016052A2 CONC2020/0016052A CO2020016052A CO2020016052A2 CO 2020016052 A2 CO2020016052 A2 CO 2020016052A2 CO 2020016052 A CO2020016052 A CO 2020016052A CO 2020016052 A2 CO2020016052 A2 CO 2020016052A2
Authority
CO
Colombia
Prior art keywords
cells
growth factor
effort
factor receptors
treatment
Prior art date
Application number
CONC2020/0016052A
Other languages
English (en)
Inventor
Nicola Kaye Price
John Stephen Bridgeman
Original Assignee
Instil Bio Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio Uk Ltd filed Critical Instil Bio Uk Ltd
Publication of CO2020016052A2 publication Critical patent/CO2020016052A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4635—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

RESUMEN TÉCNICO La terapia celular adoptiva implica la transferencia de células autólogas o alogénicas a los pacientes en un esfuerzo por tratar una variedad de enfermedades. En el área de la inmunoterapia, las células T específicas de tumores pueden cultivarse ex vivo, o injertarse con especificidad tumoral mediante enfoques de ingeniería genética, antes de la reinfusión. Las infusiones de células T requieren un tratamiento de preacondicionamiento y, a menudo, un tratamiento posterior a la infusión de IL-2, en un esfuerzo por mejorar la persistencia y el injerto. Aquí mostramos que las células T pueden diseñarse para expresar un Receptor del Factor de Crecimiento recombinante Quimérico (CrGFR) que permite la supervivencia selectiva y/o la expansión de las células T tras la administración de un fármaco clínicamente disponible, Eltrombopag.
CONC2020/0016052A 2018-06-21 2020-12-21 Receptores del factor de crecimiento quimérico CO2020016052A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810181.6A GB201810181D0 (en) 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors
PCT/GB2019/051745 WO2019243835A1 (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors

Publications (1)

Publication Number Publication Date
CO2020016052A2 true CO2020016052A2 (es) 2021-01-29

Family

ID=63042840

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0016052A CO2020016052A2 (es) 2018-06-21 2020-12-21 Receptores del factor de crecimiento quimérico

Country Status (19)

Country Link
US (1) US20210205365A1 (es)
EP (1) EP3810646A1 (es)
JP (1) JP2021527425A (es)
KR (1) KR20210022690A (es)
CN (1) CN112601759A (es)
AU (1) AU2019289202A1 (es)
BR (1) BR112020026233A2 (es)
CA (1) CA3104079A1 (es)
CL (1) CL2020003319A1 (es)
CO (1) CO2020016052A2 (es)
CR (1) CR20200624A (es)
EA (1) EA202190100A1 (es)
EC (1) ECSP20082338A (es)
GB (1) GB201810181D0 (es)
IL (1) IL279469A (es)
MX (1) MX2020014257A (es)
PH (1) PH12020500678A1 (es)
SG (1) SG11202012726QA (es)
WO (1) WO2019243835A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2021173586A1 (en) * 2020-02-24 2021-09-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
CA3205464A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
WO2022130015A2 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510744A (en) * 1998-09-23 2003-02-28 Zymogenetics Inc Cytokine receptor zalpha11
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
ES2791953T3 (es) * 2014-06-06 2020-11-06 Us Health Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2018175476A1 (en) * 2017-03-20 2018-09-27 Baylor College Of Medicine Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells

Also Published As

Publication number Publication date
SG11202012726QA (en) 2021-01-28
IL279469A (en) 2021-01-31
EA202190100A1 (ru) 2021-04-23
AU2019289202A1 (en) 2021-01-14
WO2019243835A1 (en) 2019-12-26
US20210205365A1 (en) 2021-07-08
MX2020014257A (es) 2021-07-21
KR20210022690A (ko) 2021-03-03
ECSP20082338A (es) 2021-02-26
CR20200624A (es) 2021-06-24
JP2021527425A (ja) 2021-10-14
CL2020003319A1 (es) 2021-07-09
CN112601759A (zh) 2021-04-02
EP3810646A1 (en) 2021-04-28
PH12020500678A1 (en) 2021-07-12
GB201810181D0 (en) 2018-08-08
BR112020026233A2 (pt) 2021-04-20
CA3104079A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
CO2020016052A2 (es) Receptores del factor de crecimiento quimérico
Kalaszczynska et al. Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance
Muranski et al. Adoptive immunotherapy of cancer using CD4+ T cells
Wrzesinski et al. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy
CL2017002481A1 (es) Terapia de combinación del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte progamada 1 (pd 1) para el tratamiento del cáncer
Grote et al. Toll-like receptor 2/6-dependent stimulation of mesenchymal stem cells promotes angiogenesis by paracrine factors
AR057582A1 (es) Agentes para suprimir la induccion de linfocitos t citotoxicos
Introna et al. Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms
WO2015154012A8 (en) Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
RU2017111300A (ru) Центральные т-клетки памяти для адоптивной т-клеточной терапии
ES2910115T3 (es) Células madre mesenquimales preacondicionadas con trombina para el tratamiento de la EIH neonatal
BR112014027957A8 (pt) métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer"
CO2021006259A2 (es) Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos
MX2020003945A (es) Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
CL2017002357A1 (es) Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
CO2020007275A2 (es) Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
CO2020006855A2 (es) Composiciones y métodos para el agotamiento de células cd2+
Pandey et al. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells
KR101968184B1 (ko) 저산소 조건을 이용한 면역세포의 증식 배양 방법
Petrozziello et al. Exploiting cytokines in adoptive T-cell therapy of cancer
Ludke et al. Uterine-derived progenitor cells are immunoprivileged and effectively improve cardiac regeneration when used for cell therapy
Xue et al. WT1-targeted immunotherapy of leukaemia
Krieg et al. Use of CD122+ natural killer cell precursors for superior anti-leukemia response.
CL2016001813A1 (es) Uso de gsk-j4 en la prevención y/o tratamiento del rechazo de trasplantes.